Skip to main content

U.S. Says Strikes on Militia in Iraq Sent a Warning to Iran

U.S. Says Strikes on Militia in Iraq Sent a Warning to Iran(Bloomberg) -- The U.S. air strikes on five bases in Iraq and Syria used by an Iranian-backed militia sent a warning to Tehran that President Donald Trump’s patience has its limits.“One of the things that we want to emphasize is that this was a defensive action that was designed to protect American forces and American citizens in Iraq,” Brian Hook, the State Department’s Iran envoy, said in a telephone briefing Monday. “We’re also working on the mission set of restoring deterrence against Iranian aggression.”Sunday’s rare direct strike on an Iranian proxy came at an especially tense time and held the potential for escalation. The U.S. and Iran are locked in a standoff over the Trump administration’s crippling economic offensive against Tehran -- meant to force it to renegotiate the 2015 nuclear deal Washington has abandoned -- and the Islamic Republic’s suspected reprisals.Rocket assaults on or near Iraqi installations that host American troops and personnel have occurred since the fall, and Pentagon officials have expressed increasing concern about Iranian involvement. An American contractor was killed in such an attack on Friday, and several U.S. service personnel were wounded.‘Pretty Darn Patient’“They took a strike at an American facility,” Secretary of State Michael Pompeo said Monday on “Fox and Friends.” “President Trump’s been pretty darn patient, and he’s made clear at the same time that when Americans’ lives were at risk we would respond, and that’s what the Department of Defense did yesterday.”Iraq has the potential to be a military flashpoint between the U.S. and Iran. U.S. troops are stationed in Iraq to fight Islamic State militants amid thousands of Iranian-backed Shiite militias controlled by officials in Baghdad sympathetic to Tehran.While a direct U.S.-Iran conflict remains unlikely, the latest episode “marginally increases” the risk, Ayham Kamel, head of Middle East and North Africa research at the Eurasia Group, said in a note on Monday.“There is both a clear willingness by Iran to assume greater regional risks and extract concessions from the U.S.,” Kamel and colleagues wrote. “On the U.S. side, Washington’s policy process is broken and there is a significant risk of miscalculation.”Iran condemned the attack on the Kata’ib Hezbollah militia’s bases as “an aggression against Iraqi soil and a clear example of terrorism,” the semi-official Tasnim news agency reported, quoting Abbas Mousavi, Iran’s Foreign Ministry spokesman.Vowing revenge, Kata’ib Hezbollah said in a statement, “Let Trump know that he will pay dearly in Iraq and the countries where his criminal forces are present.”Iraq’s foreign ministry said in a statement that it will summon the U.S. envoy to Baghdad to express its condemnation over the airstrikes as a “blatant” violation of its sovereignty. Iraq’s parliament speaker, Mohammed Al-Halbousi, denounced the raid even as he urged all parties to display restraint.Kata’ib Hezbollah’s parent group reported that 25 fighters were killed and 51 were wounded. The militia nominally falls under the command of the Iraqi armed forces and fought Islamic State alongside the Iraqi army and the U.S.-led coalition. But it has also been armed by Iran and is assisting it in ferrying arms to Syria, where it is propping up President Bashar al-Assad’s troops.Pompeo and Defense Secretary Mark Esper flew to Florida on Sunday to brief Trump on activities of the previous three days.Esper said in a statement that F-15 jets attacked five targets, three in western Iraq and two in eastern Syria that were either command control facilities or weapons caches. “The strikes were successful, the pilots and aircraft returned back to base safely,” he said.(Updates with analyst comment in seventh paragraph)\--With assistance from Polina Noskova, Zaid Sabah and Justin Sink.To contact the reporter on this story: Glen Carey in Washington at gcarey8@bloomberg.netTo contact the editors responsible for this story: Lin Noueihed at lnoueihed@bloomberg.net, ;Bill Faries at wfaries@bloomberg.net, Larry Liebert, Elizabeth WassermanFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.




from Yahoo Finance https://ift.tt/2SAUcjl

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be